U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H28O2
Molecular Weight 288.4251
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TESTOSTERONE

SMILES

C[C@@]12CCC(=O)C=C2CC[C@@]3([H])[C@]4([H])CC[C@@]([H])([C@@]4(C)CC[C@@]31[H])O

InChI

InChIKey=MUMGGOZAMZWBJJ-DYKIIFRCSA-N
InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1

HIDE SMILES / InChI

Molecular Formula C19H28O2
Molecular Weight 288.4251
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including

Testosterone is a steroid sex hormone found in both men and women. In men, testosterone is produced primarily by the Leydig (interstitial) cells of the testes when stimulated by luteinizing hormone (LH). It functions to stimulate spermatogenesis, promote physical and functional maturation of spermatozoa, maintain accessory organs of the male reproductive tract, support development of secondary sexual characteristics, stimulate growth and metabolism throughout the body and influence brain development by stimulating sexual behaviors and sexual drive. In women, testosterone is produced by the ovaries (25%), adrenals (25%) and via peripheral conversion from androstenedione (50%). Testerone in women functions to maintain libido and general wellbeing. Testosterone exerts a negative feedback mechanism on pituitary release of LH and follicle-stimulating hormone (FSH). Testosterone may be further converted to dihydrotestosterone or estradiol depending on the tissue. The effects of testosterone in humans and other vertebrates occur by way of two main mechanisms: by activation of the androgen receptor (directly or as DHT), and by conversion to estradiol and activation of certain estrogen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects. Testosterone is used as hormone replacement or substitution of diminished or absent endogenous testosterone. Use in males: For management of congenital or acquired hypogonadism, hypogonadism associated with HIV infection, and male climacteric (andopause). Use in females: For palliative treatment of androgen-responsive, advanced, inoperable, metastatis (skeletal) carcinoma of the breast in women who are 1-5 years postmenopausal; testosterone esters may be used in combination with estrogens in the management of moderate to severe vasomotor symptoms associated with menopause in women who do not respond to adequately to estrogen therapy alone.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P10275
Gene ID: 367.0
Gene Symbol: AR
Target Organism: Homo sapiens (Human)
3.16 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TESTOSTERONE

Approved Use

Testosterone is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: • Primary Hypogonadism (Congenital or Acquired) (1) • Hypogonadotropic Hypogonadism (Congenital or Acquired)

Launch Date

1.35950395E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
13.1 pg/mL
8.2 mg single, topical
dose: 8.2 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
TESTOSTERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
214 ng/dL
30 mg single, topical
dose: 30 mg
route of administration: topical
experiment type: single
co-administered:
TESTOSTERONE unknown
Homo sapiens
population: healthy
age:
sex:
food status:
231 ng/dL
30 mg single, topical
dose: 30 mg
route of administration: topical
experiment type: single
co-administered:
TESTOSTERONE unknown
Homo sapiens
population: healthy
age:
sex:
food status:
930.1 ng/dL
5 g 1 times / day multiple, topical
dose: 5 g
route of administration: topical
experiment type: multiple
co-administered:
TESTOSTERONE unknown
Homo sapiens
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
948 pg × h/mL
8.2 mg single, topical
dose: 8.2 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
TESTOSTERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
2120 ng*h/dL
30 mg single, topical
dose: 30 mg
route of administration: topical
experiment type: single
co-administered:
TESTOSTERONE unknown
Homo sapiens
population: healthy
age:
sex:
food status:
3110 ng*h/dL
30 mg single, topical
dose: 30 mg
route of administration: topical
experiment type: single
co-administered:
TESTOSTERONE unknown
Homo sapiens
population: healthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7 h
8.2 mg single, topical
dose: 8.2 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
TESTOSTERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
13%
8.2 mg single, topical
dose: 8.2 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
TESTOSTERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
75 mg 1 times / day steady, subcutaneous (median)
Recommended
Dose: 75 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 75 mg, 1 times / day
Sources:
unhealthy, adult
n = 150
Health Status: unhealthy
Condition: hypogonadism
Age Group: adult
Sex: M
Population Size: 150
Sources:
Disc. AE: Hypertension...
AEs leading to
discontinuation/dose reduction:
Hypertension (5.6%)
Sources:
100 mg 1 times / day steady, topical
Recommended
Dose: 100 mg, 1 times / day
Route: topical
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean 74 years
n = 106
Health Status: unhealthy
Condition: with limitations in mobility
Age Group: mean 74 years
Sex: M
Population Size: 106
Sources:
Other AEs: Cardiac disorders, Atherosclerosis...
Other AEs:
Cardiac disorders (6.5%)
Atherosclerosis (6.4%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypertension 5.6%
Disc. AE
75 mg 1 times / day steady, subcutaneous (median)
Recommended
Dose: 75 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 75 mg, 1 times / day
Sources:
unhealthy, adult
n = 150
Health Status: unhealthy
Condition: hypogonadism
Age Group: adult
Sex: M
Population Size: 150
Sources:
Atherosclerosis 6.4%
100 mg 1 times / day steady, topical
Recommended
Dose: 100 mg, 1 times / day
Route: topical
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean 74 years
n = 106
Health Status: unhealthy
Condition: with limitations in mobility
Age Group: mean 74 years
Sex: M
Population Size: 106
Sources:
Cardiac disorders 6.5%
100 mg 1 times / day steady, topical
Recommended
Dose: 100 mg, 1 times / day
Route: topical
Route: steady
Dose: 100 mg, 1 times / day
Sources:
unhealthy, mean 74 years
n = 106
Health Status: unhealthy
Condition: with limitations in mobility
Age Group: mean 74 years
Sex: M
Population Size: 106
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major [Km 10 uM]
major [Km 38.7 uM]
minor
minor
minor
minor
minor
minor
minor
minor
no
no
no
no
no
no
no
no
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
Effects of hyperprolactinemia on testosterone production in rat Leydig cells.
2001
Psychophysiological responses to the Stroop Task after a maximal cycle ergometry in elite sportsmen and physically active subjects.
2001 Feb
Spz1, a novel bHLH-Zip protein, is specifically expressed in testis.
2001 Feb
Effects of the anti-androgen finasteride on the modulatory actions of oestradiol on androgen metabolism by human gingival fibroblasts.
2001 Feb
Androgens and the role of female "hyperaggressiveness" in spotted hyenas (Crocuta crocuta).
2001 Feb
Interactions among paternal behavior, steroid hormones, and parental experience in male marmosets (Callithrix kuhlii).
2001 Feb
Castration in Gambel's and Scaled Quail: ornate plumage and dominance persist, but courtship and threat behaviors do not.
2001 Feb
Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes.
2001 Feb
Photoperiod-induced testicular apoptosis in European starlings (Sturnus vulgaris).
2001 Feb
Neuroendocrine regulation of sexually dimorphic brain structure and associated sexual behavior in male rats is genetically controlled.
2001 Feb
Influence of the degree of stimulation of the pituitary by gonadotropin-releasing hormone on the action of inhibin and testosterone to suppress the secretion of the gonadotropins in rams.
2001 Feb
Follicular-fluid factors and granulosa-cell gene expression associated with follicle deviation in cattle.
2001 Feb
Substitution mutation C268Y causes 17 beta-hydroxysteroid dehydrogenase 3 deficiency.
2001 Feb
Sex differences in androgen receptors of the human mamillary bodies are related to endocrine status rather than to sexual orientation or transsexuality.
2001 Feb
Plasma melatonin concentration before and during testosterone replacement in Klinefelter's syndrome: relation to hepatic indolamine metabolism and sympathoadrenal activity.
2001 Feb
Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.
2001 Feb
Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause.
2001 Feb
Androgen deficiency in women with hypopituitarism.
2001 Feb
Muting of androgen negative feedback unveils impoverished gonadotropin-releasing hormone/luteinizing hormone secretory reactivity in healthy older men.
2001 Feb
Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance.
2001 Feb
Disparate response of wild-type and variant forms of LH to GnRH stimulation in individuals heterozygous for the LHbeta variant allele.
2001 Feb
Estrogen and androgen elicit growth hormone release via dissimilar patterns of hypothalamic neuropeptide secretion.
2001 Feb
Testosterone concentrations in women aged 25-50 years: associations with lifestyle, body composition, and ovarian status.
2001 Feb 1
Neuronal size in the spinal nucleus of the bulbocavernosus: direct modulation by androgen in rats with mosaic androgen insensitivity.
2001 Feb 1
Luteinizing hormone-dependent activity and luteinizing hormone-independent differentiation of rat fetal Leydig cells.
2001 Feb 14
Porcine gonadal and placental isozymes of aromatase cytochrome P450: sub-cellular distribution and support by NADPH-cytochrome P450 reductase.
2001 Feb 14
Changes in androgenic steroid profile due to urine contamination by microorganisms: a prospective study in the context of doping control.
2001 Feb 15
Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate.
2001 Jan
Androgenic anabolic steroids and arterial structure and function in male bodybuilders.
2001 Jan
Targeted disruption of luteinizing hormone/human chorionic gonadotropin receptor gene.
2001 Jan
Glucocorticoids regulate plasma membrane potential during rat thymocyte apoptosis in vivo and in vitro.
2001 Jan
Differential effects of dexamethasone treatment on lipopolysaccharide-induced testicular inflammation and reproductive hormone inhibition in adult rats.
2001 Jan
Regulation of cytochrome P450 aromatase gene expression in adult rat Leydig cells: comparison with estradiol production.
2001 Jan
Testosterone-induced inhibition of spermatogenesis is more closely related to suppression of FSH than to testicular androgen levels in the cynomolgus monkey model (Macaca fascicularis).
2001 Jan
Side of ovulation, hormones and sex ratios.
2001 Jan
The female-to-male transsexual patient: a source of human ovarian cortical tissue for experimental use.
2001 Jan
On call. I know that men have more heart disease than women and that athletes who use steroids can have heart attacks. Are male hormones responsible for heart disease in ordinary men like me?
2001 Jan
Short-term 17beta-estradiol decreases glucose R(a) but not whole body metabolism during endurance exercise.
2001 Jan
Effects of testosterone on production of perivitelline membrane glycoprotein ZPC by granulosa cells of Japanese quail (Coturnix japonica).
2001 Jan
Lysyl oxidase and MMP-2 expression in dehydroepiandrosterone-induced polycystic ovary in rats.
2001 Jan
17beta-oestradiol acutely regulates Cl- secretion in rat distal colonic epithelium.
2001 Jan 1
Cross-talk between steroid-receptor-mediated and cell-membrane-receptor-mediated signalling pathways results in the in vivo modulation of c-Met and ornithine decarboxylase gene expression in mouse kidney.
2001 Jan 15
Expression of the 17beta-hydroxysteroid dehydrogenase type 5 mRNA in the human brain.
2001 Jan 22
Distribution of 17beta-hydroxysteroid dehydrogenases in human osteoblast-like cells.
2001 Jan 22
Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
2001 Jan 22
Type 5 17beta-hydroxysteroid dehydrogenase: its role in the formation of androgens in women.
2001 Jan 22
Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy.
2001 Jan 9
Effects of low-frequency magnetic fields on implantation in rats.
2001 Jan-Feb
Testosterone influences libido and well being in women.
2001 Jan-Feb
Regulation of the steroid-inducible 3alpha-hydroxysteroid dehydrogenase/carbonyl reductase gene in Comamonas testosteroni.
2001 Mar 30
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: can also be injected https://www.drugs.com/pro/testosterone.html
Starting dose of testosterone gel is 50 mg of testosterone (4 pump actuations, two 25 mg packets, or one 50 mg packet), applied once daily in the morning.
Route of Administration: Topical
10 nM Testosterone significantly reduced secretion of BDNF in in human airway smooth muscle
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:10:15 UTC 2021
Edited
by admin
on Fri Jun 25 21:10:15 UTC 2021
Record UNII
3XMK78S47O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TESTOSTERONE
EMA EPAR   EP   HSDB   INCI   INN   JAN   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
INN   INCI  
Official Name English
TESTOSTERONE [JAN]
Common Name English
TESTOSTERONE [EP MONOGRAPH]
Common Name English
TESTOSTERONE [MART.]
Common Name English
ANDROST-4-EN-3-ONE, 17-HYDROXY-, (17.BETA.)-
Systematic Name English
TESTOSTERONE ENANTATE IMPURITY D [EP]
Common Name English
INTRINSA
Brand Name English
ANDROGEL
Brand Name English
TESTOSTERONE [GREEN BOOK]
Common Name English
TESTOSTERONE [WHO-DD]
Common Name English
ANDROID-T
Brand Name English
TESTOSTERONE [EP]
Common Name English
LIVENSA
Brand Name English
TESTOSTERONE [ORANGE BOOK]
Common Name English
TESTOSTERONE [HSDB]
Common Name English
TESTOSTERONE [EMA EPAR]
Common Name English
NSC-9700
Code English
TESTIM
Code English
VOGELXO
Brand Name English
TESTOSTERONE PROPIONATE IMPURITY C [EP]
Common Name English
TESTOSTERONE [INCI]
Common Name English
ANDROLAN
Brand Name English
17.BETA.-HYDROXYANDROST-4-EN-3-ONE
Systematic Name English
NATESTO
Brand Name English
TESTICULOSTERONE
Common Name English
MERTESTATE
Common Name English
VIROSTERONE
Common Name English
TESTOSTERONE [USP]
Common Name English
TESTOSTERONE [INN]
Common Name English
TESTOSTERONE [VANDF]
Common Name English
TESTOSTERONE [MI]
Common Name English
HOMOSTERONE
Common Name English
ANDRODERM
Brand Name English
TESTOSTERONE CIII
USP-RS  
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 52590
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 49043-3
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
NDF-RT N0000175824
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 2990-0
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 76352-4
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 2986-8
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
WHO-VATC QG03EA02
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 34380-6
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 83116-4
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 59229-5
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 25987-9
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
EMA ASSESSMENT REPORTS LIVENSA (SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL )
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 26827-6
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LIVERTOX 944
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 26826-8
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
CFR 21 CFR 862.1680
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 2987-6
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
NCI_THESAURUS C2298
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
NDF-RT N0000008241
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 2993-4
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 49041-7
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 2994-2
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 13486-6
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
FDA ORPHAN DRUG 104197
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 35225-2
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 49042-5
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 59240-2
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
FDA ORPHAN DRUG 523916
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 59233-7
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
WHO-VATC QG03BA03
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 2988-4
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 16286-7
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 15095-3
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 31030-0
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
WHO-ATC G03EA02
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
WHO-ATC G03BA03
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 73570-4
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 2984-3
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 15432-8
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 2991-8
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 14914-6
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 41018-3
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 35224-5
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 2992-6
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 17685-9
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 59219-6
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
EMA ASSESSMENT REPORTS INTRINSA (WITHDRAWN: SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL)
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 48357-8
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
FDA ORPHAN DRUG 94595
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 10631-0
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 51005-7
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 18.2
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 27306-0
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
CFR 21 CFR 862.1430
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 70239-9
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
CFR 21 CFR 310.528
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 70240-7
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 15094-6
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 2985-0
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 2989-2
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 6891-6
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 83115-6
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 14913-8
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 17687-5
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
DEA NO. 4000
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
LOINC 25986-1
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
NDF-RT N0000000146
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
Code System Code Type Description
ECHA (EC/EINECS)
200-370-5
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY
WIKIPEDIA
TESTOSTERONE
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY
CAS
58-22-0
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY
MESH
D013739
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY
HSDB
3398
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY
IUPHAR
2858
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY
DRUG BANK
DB00624
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY
INN
1900
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY
NCI_THESAURUS
C862
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY
FDA UNII
3XMK78S47O
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY
PUBCHEM
6013
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY
ChEMBL
CHEMBL386630
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY
LACTMED
Testosterone
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY
EPA CompTox
58-22-0
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY
RXCUI
10379
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY RxNorm
USP_CATALOG
1646009
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY USP-RS
EVMPD
SUB10937MIG
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY
DRUG CENTRAL
2607
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY
MERCK INDEX
M10594
Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
PRIMARY Merck Index
Related Record Type Details
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
In reproductive tissues, dihydrotestosterone is further metabolized to 3-alpha and 3-beta androstanediol
METABOLITE TOXIC -> PARENT
Metabolite shown to induce pyrogenic and inflammatory reactions in man.
PARENT -> METABOLITE
URINE
METABOLITE ACTIVE -> PARENT
DHT binds with greater affinity to SHBG than does testosterone
MAJOR
METABOLITE -> PARENT
In reproductive tissues, dihydrotestosterone is further metabolized to 3-alpha and 3-beta androstanediol
METABOLITE -> PARENT
PRODRUG -> METABOLITE ACTIVE
METABOLITE ACTIVE -> PARENT
PRODRUG -> METABOLITE ACTIVE
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY